TENOSYNOVIAL GIANT CELL TUMOR
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an experimental drug called vimseltinib for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and stiffness. The trial includes 123 adults whose tumors cannot be removed by surgery. Participants receive …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
New hope for rare joint tumor: drug shrinks growths without surgery
Disease control OngoingThis study tests a drug called pexidartinib in 40 adults with a rare joint tumor (TGCT) that causes severe symptoms and cannot be helped by surgery. The main goal is to see if the drug shrinks the tumors after 25 weeks of treatment. Participants take the drug daily and are monito…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
Hope for rare joint tumor: new drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug called Pimicotinib (ABSK021) for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that grows in joints and tendons. About 94 adults with tumors that cannot be removed by surgery will receive either the drug or a placebo for…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New drug shows promise for rare joint tumor – but not a cure
Disease control OngoingThis study tests an experimental drug called vimseltinib in people with a rare joint tumor (TGCT) or advanced solid tumors. The goal is to find the safest dose and see if it shrinks tumors or improves symptoms. About 120 adults will take part. This is not a cure – the drug aims t…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for rare joint tumor: drug targets tough cases
Disease control OngoingThis study tests a drug called pexidartinib in 9 adults in Japan who have a rare, non-cancerous joint tumor (TGCT) that causes severe problems and cannot be helped by surgery. The goal is to see if the drug can shrink the tumor and improve joint movement, while checking for side …
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE2 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC